Several FLT3 inhibitors, including gilteritinib, quizartinib (AC220) and midostaurin7, have been approved for the treatment of FLT3-ITD+ and/or TKD+ AML patients via using an FDA-approved test. This evidence concerns the gene FLT3 and acute myeloid leukemia.